Jove
Visualize
Contact Us

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Blood-based Microrna Biomarker Signature Of Early-stage Pancreatic Ductal Adenocarcinoma With Lead-time Trajectory In Prediagnostic Samples.
  1. Home
  3. Blood-based Microrna Biomarker Signature Of Early-stage Pancreatic Ductal Adenocarcinoma With Lead-time Trajectory In Prediagnostic Samples.

Related Experiment Video

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in

Warapen Treekitkarnmongkol1, Jianliang Dai2, Suyu Liu2

  • 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Gastro Hep Advances
|November 12, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

A novel three-miRNA signature in plasma shows promise for early pancreatic ductal adenocarcinoma (PDAC) detection, outperforming CA19-9. This biomarker aids in distinguishing PDAC from pancreatitis and offers improved early diagnosis potential.

Keywords:
Early Detection BiomarkersLiquid BiopsyPancreatic Ductal AdenocarcinomaPlasma miRNAProstate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

More Related Videos

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Related Experiment Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) diagnosis is challenged by the limited sensitivity and specificity of current biomarkers like carbohydrate antigen 19-9 (CA19-9), especially in early stages.
  • Circulating microRNAs (miRNAs) in plasma represent a potential source for novel, non-invasive biomarkers for early cancer detection.

Purpose of the Study:

  • To develop and validate a plasma-based miRNA signature for the early detection of pancreatic ductal adenocarcinoma (PDAC).
  • To assess the diagnostic performance of the miRNA signature in differentiating PDAC from healthy controls and pancreatitis patients.
  • To evaluate the signature's ability to improve early detection in a prediagnostic cohort.

Main Methods:

  • Interrogation of 2083 miRNAs from plasma samples across multicenter cohorts, including healthy controls, pancreatitis controls, and diagnosed PDAC cases (N=203).
  • Development of a three-miRNA biomarker signature (let-7i-5p, miR-130a-3p, miR-221-3p) for early-stage PDAC detection.
  • Validation in an independent prediagnostic cohort (N=96) and assessment of performance in combination with CA19-9.

    • Main Results:

    • The three-miRNA signature demonstrated high diagnostic accuracy for PDAC detection (AUC = 0.970-0.975) and significantly improved performance when combined with CA19-9 (AUC = 0.992-1.000).
    • The signature effectively discriminated between PDAC and chronic pancreatitis (AUC = 0.929-0.932), outperforming CA19-9 alone.
    • In the prediagnostic cohort, the signature showed an increasing AUC trend (0.702 to 0.757) in the months preceding PDAC diagnosis, indicating lead-time potential.

    Conclusions:

    • Plasma-based circulating miRNAs hold significant potential as early detection biomarkers for pancreatic ductal adenocarcinoma (PDAC).
    • The developed three-miRNA signature offers a promising tool for improving the early diagnosis and differentiation of PDAC.
    • Further research into miRNA biomarkers could enhance non-invasive cancer diagnostics and patient stratification.